Crosstex Acquires SPSmedical, Uniting Sterilization Monitoring and Assurance Leaders
The addition of SPSmedical to the Crosstex family strengthens the Crosstex position in the acute-care and alternate-care markets while broadening the Crosstex sterility assurance product offering. Based in Rochester, N.Y., SPS is a leading manufacturer and provider of biological and chemical indicators for sterility assurance monitoring services and products. SPS offers a wide-array of products and services that enable hospitals, surgery centers, office-based practitioners and dental offices to safely and accurately monitor and verify their sterilization practices and protocols.
According to Gary Steinberg, president and CEO of Crosstex, "SPSmedical is the perfect complement to our ConFirm brand biologic monitoring business and will provide us with the platform to broaden our reach into the acute-care and alternate-care markets. SPS' strong leadership in defining and establishing sterility assurance standards in healthcare settings is a strong platform upon which Crosstex can expand its global presence as a leader in the healthcare infection prevention and control market."
"The addition of SPS to the Crosstex family expands our presence in the acute-care and alternate-care markets, broadens our product portfolio and strengthens our position in the dental market," said Andrew Whitehead, senior vice president of business development. "Utilizing the strengths, reputations and talent of the combined Crosstex and SPS teams, we will increase our market penetration into all healthcare channels, both domestically and internationally."
Learn more about Crosstex.
© Copyright ASC COMMUNICATIONS 2016. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.
To receive the latest hospital and health system business and legal news and analysis from Becker's Hospital Review, sign-up for the free Becker's Hospital Review E-weekly by clicking here.
- Surgery Center of Cliffside receives accreditation
- 4 GI physicians in the news — July 29, 2016
- Takeda Pharmaceutical plans $725M R&D redesign: 5 things to know
- Dr. James Cottrell wins Arthur Ashe Institute for Urban Health's leadership award: 5 notes
- Anthem to add 9 ACA exchanges if Cigna deal passes: 4 takeaways